Brittanie M. Volk

Brittanie M. Volk

Auto-generated profile, based on publicly available information

Brittanie M. Volk

The Ketogenic Foundation, Napa, CA, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2017 in JMIR Diabetes
Verified
Journal Article
Open access
Amy McKenzieAmy McKenzie
Amy McKenzie
SHSarah Hallberg
Sarah Hallberg
BCBrent C Creighton
Brent C Creighton
BVBrittanie M Volk
Brittanie M Volk
TLTheresa M Link
Theresa M Link
SPStephen Phinney
Stephen Phinney
Emerging Technologies, Medical Devices, Apps, Sensors, and Informatics to Help People with Diabetes

19 October 2024 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
Amy McKenzieAmy McKenzie
Amy McKenzie
Shaminie AthinarayananShaminie Athinarayanan
Shaminie Athinarayanan
MTMichelle R. Van Tieghem
Michelle R. Van Tieghem
BVBrittanie M. Volk
Brittanie M. Volk
CRCaroline G.P. Roberts
Caroline G.P. Roberts
SHSarah J. Hallberg
Sarah J. Hallberg
This study assessed the five-year effects of a continuous care intervention (CCI) delivered via telemedicine, counseling people with type 2 diabetes (T2D) on a very low carbohydrate diet with nutritional ketosis. Participants with T2D were enrolled in a 2-year, open-label, non-randomized study comparing CCI and usual care (UC). After 2 years, 194 of the 262 CCI participants were approached for a three-year extension. Of these, 169 consented, and 122 remained in the study for five years. Primary outcomes were changes in diabetes status assessed using McNemars' test, including remission and HbA1c < 6.5 % on no glucose lowering medication or only on metformin at 5 years. Changes in body mass, glycemia, and cardiometabolic markers from baseline to 5 years were assessed using linear mixed-effects models. Twenty percent (n = 24) of the five-year completers achieved remission, with sustained remission observed over three years in 15.8 % (n = 19) and four years in 12.5 % (n = 15). Reversal to HbA1c < 6.5 % without medication or only metformin was seen in 32.5 % (n = 39). Sustained improvements were noted in body mass (-7.6 %), HbA1c (-0.3 %), triglycerides (-18.4 %), HDL-C (+17.4 %), and inflammatory markers, with no significant changes in LDL-C and total cholesterol. Over five years, the very low carbohydrate intervention showed excellent retention and significant health benefits, including diabetes remission, weight loss, and improved cardiometabolic markers.

1 July 2022 in BMJ Nutrition, Prevention & Health
Verified
Journal Article
Open access
PDF file
BVBrittanie M Volk
Brittanie M Volk
CRCaroline G P Roberts
Caroline G P Roberts
MVMichelle VanTieghem
Michelle VanTieghem
MGM Patricia George
M Patricia George
RARebecca N Adams
Rebecca N Adams
AMAmy L McKenzie
Amy L McKenzie
Objective To investigate factors associated with COVID-19 severity in ambulatory individuals with type 2 diabetes mellitus (T2DM) and obesity treated with a medically supervised ketogenic diet (MSKD). Research design and methods In this real-world, retrospective, exploratory analysis, multivariate modelling was used to assess clinical factors associated with hospitalisation for COVID-19 in a geographically diverse outpatient population with T2DM treated virtually. Results Leading up to COVID-19 onset, non-hospitalised patients had higher average ketones (0.64 vs 0.52 mmol/L; p=0.016) and greater weight loss (6.8% vs 4.2%; p=0.009) compared with those hospitalised. Greater weight loss was significantly associated with lower likelihood of hospitalisation (adjusted OR=0.91, p=0.005), controlling for enrolment demographics and medical characteristics. Conclusions Therapies such as MSKD, which elicit rapid, significant weight loss, may favourably impact COVID-19 hospitalisation rate and severity in individuals with T2DM and obesity.

1 January 2013
Verified
Book Chapter
Closed access
BVBrittanie M. Volk
Brittanie M. Volk
BCBrent C. Creighton
Brent C. Creighton

1 April 2013 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
BKBrian Richard Kupchak
Brian Richard Kupchak
BVBrittanie M Volk
Brittanie M Volk
LKLauren Kunces
Lauren Kunces
LPLauren Phinney
Lauren Phinney
Martin HoffmanMartin Hoffman
Martin Hoffman
JVJeff Volek
Jeff Volek
The aim of this study was to examine coagulation and fibrinolytic responses in runners competing in the Western States Endurance Run (WSER, June 23 to 24, 2012). The WSER is a 160‐km trail foot race through the Sierra Nevada Mountains that involves 15,540 ft of climb and 22,970 ft of descent. We examined 12 men and 4 women (mean±SE, age 44.6±3.0 y), who completed the race (24.64±1.07 hrs). Blood samples were collected the morning before the race, immediately post‐race, and 1 (D1) and 2 (D2) days post‐race (corresponding to 51 – 54 hr, and 75 – 78 hr from the start of the race, respectively). Muscle damage was assessed by serum creatine kinase (CK) and myoglobin. Hypercoagulable state was characterized by prothrombin fragment 1+2 (PTF 1+2) and thrombin‐antithrombin complex. Fibrinolytic state was assessed by plasminogen activator inhibitor antigen (PAI‐1 Ag), tissue plasminogen activator antigen (tPA Ag), and D‐Dimer. Significant increases were measured immediate post‐race for thrombin generation markers, PTF 1+2 and TAT; markers of fibrinolysis, tPA Ag, PAI‐1 Ag, and D‐Dimer; muscle damage markers, CK and myoglobin. Most markers returned to baseline levels at D1, except for PTF 1+2 and D‐Dimer. Muscle damage markers, CK and myoglobin; also continued to be elevated at D1 and D2 time points. In spite of these increases, no clinical evidence of vascular occlusion was observed following the race. In conclusion, the WSER produced extensive muscle damage and activated both the coagulation and fibrinolytic systems. Moreover, these systems are in balance thus limiting the potential of a thrombotic episode.

1 March 2008 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
DKDiana M Kawiecki
Diana M Kawiecki
DFDaniel J Freidenreich
Daniel J Freidenreich
EQErin E Quann
Erin E Quann
CLCherise C Labonte
Cherise C Labonte
MPMichael J Puglisi
Michael J Puglisi
JVJeff Volek
Jeff Volek
Ketogenic diets were recently shown to induce hepatic expression and increase circulating levels of fibroblast growth factor 21 (FGF‐21), which coordinates lipid homeostasis by inducing hepatic lipid oxidation, ketogenesis, lipolysis, and triglyceride clearance. Very low carbohydrate ketogenic diets (VLCKD) in humans consistently improve features of metabolic syndrome. We hypothesized a VLCKD would increase FGF‐21 in adults. Fasting serum FGF‐21 concentrations were measured by RIA in 39 overweight men and women who consumed a VLCKD (1504 kcal:%CHO:fat:protein=12:59:28) or a low fat diet (LFD) (1478 kcal:%CHO:fat:protein=56:24:20) for 12 weeks. All subjects had detectable levels of FGF‐21 in serum with no gender differences. FGF‐21 was reduced (p<0.05) by the VLCKD (2.51 ± 0.75 to 2.19 ± 0.56) and unchanged after the LFD (3.02 ± 0.61 to 3.03 ± 0.69). Baseline concentrations and delta changes in FGF‐21 were not correlated with weight loss, body fat, glucose, insulin, lipoproteins, or other metabolic syndrome markers. Contrary to our expectations, these findings indicate that serum FGF‐21 concentrations decrease after a hypocaloric, ketogenic diet in overweight humans. The metabolic significance of this response is unclear, but may represent a down‐regulation in the need for lipolytic signaling as a consequence of the potent stimulatory effects of carbohydrate restriction on hepatic lipid oxidation.